Newsroom

Pharma’s Almanac: Artificial Intelligence (AI) Trends in Biopharma

Pharma's Almanac

In this edition of Pharma's Almanac, industry experts, including Josh Ludwig, Global Director of ScaleReady, discuss increased innovation and adoption of artificial intelligence (AI) and machine learning in biopharma.

Cell & Gene Therapy Insights: D More with Less Cell Culture in Immune Cell Therapies

Cell & Gene Therapy Insights

In this expert roundtable, David McCall, Senior Editor, BioInsights, speaks to Anastasiya Smith, Senior Director of R&D, CellReady; Josh Ludwig, Global Director, Commercial Operations, ScaleReady; and David Hermanson, Senior Manager of R&D Applications, Cell and Gene Therapy, Bio-Techne.

Cellular Origins Partners With ScaleReady to Simplify, Standardize, and Automate Cell Therapy Manufacturing

Business Wire

Partnership aims to integrate ScaleReady’s CGT manufacturing workflow with Cellular Origins’ robotic technology Initially focussed on automation of ScaleReady’s G-Rex^® platform

BioCentury: Cell and gene therapy must prioritize simplification, standardization before focusing on automation

BioCentury

Josh Ludwig, Global Director of Commercial Operations at ScaleReady, reviews how the industry is addressing the challenges that come with scaling up production to meet growth and demand and the…

Phacilitate: Early Adoption and Partnerships – The Secret to Commercialization Success?

Phacilitate

Terumo’s Stuart Gibb, Ph.D., at Terumo Blood and Cell Technologies, is joined by Nisha C. Durand, PhD, at Mayo Clinic and Matthew M. Hewitt, B.A. Ph.D., Charles River.

Bio-Techne Announces Investment in Wilson Wolf

PR Newswire

Bio-Techne Corporation announced Wilson Wolf Manufacturing has met the trailing 12-month earnings before interest, taxes, depreciation, and amortization (EBITDA) target of $55 million, triggering Bio-Techne's initial investment in the company, which…

For the Record – Medical Alley Interview with Josh Ludwig

Medical Alley

Catch up with the editors from Medical Alley as they interview ScaleReady Global Commercial Director, Josh Ludwig for their regular leadership platform, "For the Record".

Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf

HOUSTON, April 26, 2022 (GLOBE NEWSWIRE) -- -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of…

Bio-Techne Announces Future Wilson Wolf Purchase Agreement

Bio-Techne

Bio-Techne announced it has entered into a purchase option agreement with Wilson Wolf Corporation, solidifying resources and support for ScaleReady to supply the entire field of cell and gene therapy…

ScaleReady Launches Second Generation of Wilson Wolf G-Rex^® Product

The second generation G-Rex^®500M-CS improves on the materials and ergonomics of the original G-Rex^® while retaining the same cell expansion performance. St. Paul, MN, November 10, 2021 – ScaleReady announced…

Bio-Techne Releases First GMP-grade Cytokines from New GMP Facility

Bio-Techne

ScaleReady sources Bio-Techne cytokines because of their commitment to supplying the entire cell and gene therapy industry with GMP-grade, animal free proteins. Bio-Techne recently launched its new, dedicated GMP facility.

CancerNetworks Interviews ScaleReady

cancernetwork.com

Josh Ludgwig, Global Director of Commercial Operations at ScaleReady discusses what makes the company uniquely positioned to support manufacturing across the entire cell and gene therapy industry. This interview is…